942047-63-4 Usage
Description
MELOXICAM-D3 is a deuterated analog of meloxicam, a selective inhibitor of cyclooxygenase-2 (COX-2) enzyme. It is a yellow solid and is primarily used as an internal standard for the quantification of meloxicam by gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS). Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory properties by selectively inhibiting COX-2, which plays a crucial role in the production of prostaglandins involved in inflammation and pain.
Uses
Used in Pharmaceutical Industry:
MELOXICAM-D3 is used as an internal standard for the quantification of meloxicam in pharmaceutical analysis. It helps in accurately determining the concentration of meloxicam in various formulations, ensuring the quality and efficacy of the drug.
Used in Anti-inflammatory Applications:
MELOXICAM-D3 serves as a reference for meloxicam, which is used as an anti-inflammatory agent. Meloxicam, through its selective inhibition of COX-2, reduces inflammation and pain by decreasing the production of prostaglandins. It has been used in the treatment of conditions such as osteoarthritis and rheumatoid arthritis.
Used in Ocular Inflammation Research:
MELOXICAM-D3 is used as a reference for meloxicam in studies involving ocular inflammation. Meloxicam has been shown to reduce croton oil-induced increases in TNF-α and IL-1β mRNA levels and increase IL-10 mRNA levels in the cornea in a rabbit model of acute ocular inflammation.
Used in Pleurisy Research:
MELOXICAM-D3 is used as a reference for meloxicam in research involving pleurisy. In a carrageenan-induced rat model of pleurisy, meloxicam inhibits pleural plasma exudation when administered at a dose of 3 mg/kg.
Used in Osteoarthritis Research:
MELOXICAM-D3 is used as a reference for meloxicam in studies involving osteoarthritis. In a canine model of unilateral osteoarthritis of the right stifle joint, meloxicam reduces prostaglandin E2 (PGE2) levels in plasma and right stifle joint synovial fluid when administered at a dose of 0.2 mg/kg.
References
1. Ogino, K., Hatanaka, K., Kawamura, M., et al. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1. Pharmacology 55, 44-53 (1997).2. Cruz, R., Quintana-Hau, J.D., González, J.R., et al. Effects of an ophthalmic formulation of meloxicam on COX-2 expression, PGE2 release, and cytokine expression in a model of acute ocular inflammation. Br. J. Ophthalmol. 92, 120-125 (2008).3. Jones, C.J., Streppa, H.K., Harmon, B.G., et al. In vivo effects of meloxicam and aspirin on blood, gasteric mucosal, and synovial fluid prosanoid synthesis in dogs. Am. J. Vet. Res. 63, 1527-1531 (2002).
Check Digit Verification of cas no
The CAS Registry Mumber 942047-63-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,4,2,0,4 and 7 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 942047-63:
(8*9)+(7*4)+(6*2)+(5*0)+(4*4)+(3*7)+(2*6)+(1*3)=164
164 % 10 = 4
So 942047-63-4 is a valid CAS Registry Number.
942047-63-4Relevant articles and documents
Synthesis of deuterium-labelled meloxicam and piroxicam
Balssa, Frederic,Bonnaire, Yves
, p. 207 - 210 (2008/01/03)
Four step syntheses of deuterium-labelled meloxicam and piroxicam from saccharin via selective CD3I alkylation are described. Labelled oxicams are of great interest for qualitative and/or quantitative isotope dilution-mass spectrometry, coupled with liquid chromatography, currently performed in anti-doping and forensic laboratories. Copyright
